Illumina, Inc. (ILMN) — ESG & Values Scores

Environment story

Illumina reports Net Zero commitments by 2050 verified by the Science Based Target Initiative (SBTi) with 1.5°C alignment pathway, indicating credible long-term decarbonization strategy. However, Scope 1 and Scope 2 emissions are not disclosed in the 10-K filing, and Scope 3 supply-chain emissions remain undisclosed, triggering regulatory deductions. Manufacturing operations in Singapore, UK, and Netherlands consume water and energy; recycling and waste-reduction initiatives are mentioned but not quantified. No documented environmental controversies or fines appear in recent filings. Renewable energy investments are stated but specifics on % electricity from renewables are absent. The company acknowledged climate-change physical and regulatory risks in business planning and established emission reduction targets, but lacks transparency on current emissions intensity and year-on-year progress.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Net Zero Commitment with SBTi Verification

Company established Net Zero emission commitments by 2050 and targets in line with 1.5°C pathway, verified by Science Based Target Initiative.

Credible long-term framework for Scope 1 & 2 operational decarbonization; does not address supply-chain (Scope 3) emissions or near-term interim targets.
Renewable Energy and Energy Efficiency Programs

Investment in renewable energy, reduction of energy and water consumption, greenhouse gas emissions, and waste production mentioned in corporate responsibility framework.

Directional commitment; lack of quantified targets, baseline, or verification metrics in 10-K filing limits credibility assessment.
Manufacturing Capacity Expansion with Automation

Continued increase in manufacturing capability and capacity, with automation of manufacturing processes to accelerate throughput and improve quality and yield.

Scaling production efficiency may improve per-unit energy intensity; not framed as explicit climate or GHG reduction initiative.

Social story

Illumina reports a global workforce of approximately 8,600 full-time employees, 50 part-time employees, and 1,430 contingent workers as of December 28, 2025, with a voluntary turnover rate of 8% in 2025—within healthy industry range. CEO-to-median-worker pay ratio is not disclosed in the 10-K filing, preventing verification of pay equity. The company states commitment to attracting and retaining talent and supporting employee health, safety, and well-being, but specific metrics on leadership diversity (executive and board composition percentages) are deferred to the Corporate Responsibility Report and proxy filing, which are not provided here. No documented labor union suppression, strikes, or major labor controversies appear in the 10-K. Supply-chain ethical audits are not detailed; the company sources electronic components and chemical/biochemical materials from multiple vendors, with some single-source dependencies, but no specific human-rights or conflict-minerals due-diligence disclosures are included in the filing. Regional workforce distribution across Americas (4,740), Europe (1,280), Africa/Middle East/Asia (2,350), and Greater China (290) indicates global diversity, but no intersectional demographic breakdown is provided.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Human Capital Development and Talent Retention Strategy

Key objectives include recruiting and retaining top talent, supporting employee health, safety, and well-being, and engaging employees and communities. Company commits to making Illumina a place where everyone can belong and embraces new perspectives.

Strategic framework; quantified outcomes and diversity metrics not disclosed in 10-K filing.
Global Workforce Distribution and Regional Presence

Maintains offices, labs, and manufacturing facilities across Americas (4,740 employees), Europe (1,280), Africa/MEEA (2,350), and Greater China (290), supporting local talent ecosystems.

Geographic diversity supports local economies and knowledge transfer; labor standards and workplace conditions by region not detailed.
Annual Corporate Responsibility Reporting

Company publishes annual Corporate Responsibility Report guided by GRI, SASB, and TCFD frameworks, with detailed workforce and diversity data expected in April 2026.

Transparency commitment; 2025 data not yet available in this 10-K filing; dependent on third-party credibility of disclosure.

Governance story

Illumina is a large accelerated filer with single-class common stock structure ($0.01 par value) traded on Nasdaq under ticker ILMN, indicating standard governance framework without dual-class voting complications. Board independence, committee composition, and executive-compensation ratios are deferred to the proxy statement (incorporated by reference) and are not disclosed in the 10-K body. The company filed a securities class action lawsuit notification dated January 9, 2024, indicating potential past shareholder disputes, but no pending antitrust, consumer-safety, or financial-fraud regulatory proceedings are detailed in the Risk Factors section. Lobbying expenditures are not disclosed in the 10-K. The company maintains an Audit Committee responsible for cybersecurity and IT risk governance, with a Chief Information Officer and Chief Information Security Officer (20+ years experience) providing regular updates to the Board. No evidence of anti-shareholder litigation to block climate or ESG proposals appears in the filing. The company disclosed China listing on an "unreliable entities list" by Chinese regulatory authorities as a forward-looking risk, which may create geopolitical governance exposure but does not constitute a direct governance violation.

Criticisms on file

Securities Class Action Litigation
Source: ILMN 10-K, Item 3 Legal Proceedings; Motion filed January 9, 2024; underlying case filing date November 11, 2023
China 'Unreliable Entities List' Designation
Source: ILMN 10-K, Risk Factors section; stated as forward-looking risk regarding uncertainty of impact on business operations and regulatory compliance in China market

Disclosed initiatives

Integrated Cybersecurity Risk Management Program

Information security team deployed with Chief Information Security Officer (20+ years experience) leading threat identification, incident response, and third-party risk monitoring. Cybersecurity program evaluated against NIST Cybersecurity Framework. Audit Committee and Board of Directors receive regular updates on security risks and incident resolution.

Proactive governance of emerging IT/cybersecurity risks; mitigation of data breach and operational-continuity risk; maintains cybersecurity insurance.
Quality Management System and ISO 13485 Certification

Manufacturing and distribution facilities operate under quality management system certified to ISO 13485; adherence to federal, state, and local health ordinances for use, handling, and disposal of hazardous substances.

Third-party certification demonstrates commitment to product safety and regulatory compliance; supports medical-device market access.
Third-Party Risk Management for Suppliers

Established third-party risk management program to monitor suppliers with access to company information systems and critical materials.

Reduces supply-chain continuity and data-breach risk; does not explicitly address labor or human-rights supplier vetting.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Illumina, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Illumina, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)